Huijing Tang

发表

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies

Lin Zhao, Xiuxiu Xu, Shu-lan Zhang, 2022, Frontiers in Immunology.

Molecular Typing of Gastric Cancer Based on Invasion-Related Genes and Prognosis-Related Features

Qi Zhao, X. Hou, Haonan Guo, 2022, Frontiers in Oncology.

A20 inhibits periodontal bone resorption and NLRP3-mediated M1 macrophage polarization.

Xuanwen Xu, Yu Ye, Huiqing Gou, 2022, Experimental cell research.

Tryptophan 2,3-dioxygenase may be a potential prognostic biomarker and immunotherapy target in cancer: A meta-analysis and bioinformatics analysis

Huijing Tang, Zhongjian Liu, Yanyan Hu, 2022, Frontiers in Oncology.

Chronic inflammation, cancer development and immunotherapy

X. Yang, Yuchen Gao, Yi Zhu, 2022, Frontiers in Pharmacology.

Characteristics and Prognostic Nomogram for Primary Lung Lepidic Adenocarcinoma

Yingyi Wang, C. Bai, Huijing Tang, 2022, Canadian respiratory journal.

A20 alleviated caspase-1-mediated pyroptosis and inflammation stimulated by Porphyromonas gingivalis lipopolysaccharide and nicotine through autophagy enhancement

Yan Xu, Yu Ye, Lu Li, 2022, Human Cell.

Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma

Ying-Yue Wang, Shuangni Yu, Yuzhou Wang, 2022, Frontiers in Immunology.

The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis.

Chengyu Wu, Yu Ye, Yan Xu, 2019, Pathology, research and practice.

Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data

Yingyi Wang, M. Dai, Junchao Guo, 2022, Neoplasia.

POSTN Secretion by Extracellular Matrix Cancer-Associated Fibroblasts (eCAFs) Correlates with Poor ICB Response via Macrophage Chemotaxis Activation of Akt Signaling Pathway in Gastric Cancer

Jin Gao, R. Zhao, B. Wu, 2023, Aging and disease.

Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients

Xiuxiu Xu, Yuan Liu, Taisheng Li, 2023, Frontiers in Immunology.

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer

Yingyi Wang, Yanjie Han, Yuan Liu, 2023, Frontiers in Oncology.

circRNA-AKT1 Sequesters miR-942-5p to Upregulate AKT1 and Promote Cervical Cancer Progression

Liang Zhao, Rongying Ou, Yunsheng Xu, 2020, Molecular therapy. Nucleic acids.

Necroptosis-related signatures identify two distinct hepatocellular carcinoma subtypes: Implications for predicting drug sensitivity and prognosis

Zhenwei Guo, Zhao Sun, Ying-Yue Wang, 2023, Heliyon.

Extracellular Matrix-Based Gene Expression Signature Defines Two Prognostic Subtypes of Hepatocellular Carcinoma With Different Immune Microenvironment Characteristics

Yingyi Wang, Zhao Sun, C. Bai, 2022, Frontiers in Molecular Biosciences.

Patients with non‐functional metastatic G2 pancreatic neuroendocrine tumor benefit from palliative surgery: A 20‐year single‐center retrospective analysis

Xiuxiu Xu, Yue-juan Cheng, H. Ying, 2022, Journal of neuroendocrinology.

A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma

Huijing Tang, Yuping Ge, Tingting You, 2023, BMC Cancer.

A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma

Zhao Sun, C. Bai, Huijing Tang, 2022, BMC Cancer.

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma

Yue-juan Cheng, Ying-Yue Wang, C. Bai, 2023, Cancer Biology and Medicine.

Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma.

Zhao Sun, Huijing Tang, Qin Han, 2024, International immunopharmacology.